Arbutus Biopharma Corporation (ABUS) is a Biotechnology company in the Healthcare sector, currently trading at $4.35. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is ABUS = $9 (+95.4% upside).
Valuation: ABUS trades at a trailing Price-to-Earnings (P/E) of -25.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.44.
Financials: revenue is $14M, +2.9%/yr average growth. Net income is $34M (loss), growing at +17.1%/yr. Net profit margin is -237.9% (negative). Gross margin is 97.4% (+1.1 pp trend).
Balance sheet: total debt is $4M against $77M equity (Debt-to-Equity (D/E) ratio 0.05, conservative). Current ratio is 15.73 (strong liquidity). Debt-to-assets is 4.4%. Total assets: $95M.
Analyst outlook: 8 / 10 analysts rate ABUS as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 63/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 52/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
